Bridgeway Capital Management’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Bridgeway Capital Management’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-821	Closed	-$49.9K	–	1398
2023 Q1	$49.9K	Hold	821	–	–	﹤0.01%	1311
2022 Q4	$75.5K	Hold	821	–	–	﹤0.01%	1256
2022 Q3	$99K	Hold	821	–	–	﹤0.01%	1270
2022 Q2	$63K	Hold	821	–	–	﹤0.01%	1271
2022 Q1	$128K	Buy	+821	New	+$19.8K	﹤0.01%	1238
2021 Q2	–	Sell	-854	Closed	-$334K	–	1349
2021 Q1	$334K	Buy	854 +271	+46%	+$20.4K	0.01%	1205
2020 Q4	$250K	Sell	583 -210	-26%	-$14.3K	0.01%	1162
2020 Q3	$675K	Buy	793 +357	+82%	+$40.8K	0.02%	794
2020 Q2	$361K	Buy	+436	New	+$36.5K	0.01%	973

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bridgeway Capital Management's KRSA Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2023, closing a stake of 821 shares — an estimated $49.9K sold.

Bridgeway Capital Management first reported a position in KRSA in Q2 2020 and held it in 9 quarters. The position peaked at $675K in Q3 2020. 17 funds tracked by Wall St. Rank hold KRSA as of Q2 2023.

Bridgeway Capital Management reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 821 Korsana Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $49.9K.
Bridgeway Capital Management first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
Bridgeway Capital Management's Korsana Biosciences, Inc. Common Stock position peaked at $675K in Q3 2020.
17 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.